Special Issue

Metals in Cancer Research: Beyond Platinum Metallodrugs

Message from the Guest Editors

Cancer remains a formidable global health challenge. For decades, platinum-based drugs have been a cornerstone of metal-based chemotherapy. In addition, the superior platinum drug (Oxaliplatin) significantly induces immunogenic cell death (ICD). Yet their efficacy is often hampered by severe side effects and the development of acquired resistance. This has spurred the scientific community to explore innovative alternatives "beyond platinum." Non-platinum transition metal complexes-including ruthenium, iridium, gold, and others—have emerged as highly promising candidates. These complexes offer unique chemical properties, reduced systemic toxicity, and novel mechanisms of action, such as mitochondrial targeting, photodynamic therapy, and the ability to overcome drug efflux pumps. This Special Issue is dedicated to showcasing the latest advances in the design, synthesis. and application of these next-generation metal-based anticancer agents, highlighting their potential to enable more precise, effective, and safer cancer therapies.

Guest Editors

Prof. Dr. Wukun Liu

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

Dr. Zhongren Xu

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

Deadline for manuscript submissions

15 May 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/260674

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

